Building the foundation for MP4
The evolution and development of MP4 is based on research spanning over 30 years. Clinical studies evaluating the safety and efficacy of MP4 have enrolled more than 1,000 subjects in the European Union and the United States. The discoveries arising from this research have been patented and published in numerous scientific articles.
These clinical studies have demonstrated MP4OX's colloid properties and safety profile and provide the rationale for our planned clinical approach in ischemia.
The future of MP4
Phase 2b and Phase 1b clinical trials of MP4 in the therapeutic areas of trauma and sickle cell disease, respectively, are currently underway. In these two areas, patients are in significant need of medicines that can provide rapid therapeutic oxygen and carbon monoxide delivery. Click here for more information about trauma and sickle cell anemia.
With a strong foundation in scientific research, Sangart’s current clinical approach is built upon more than 30 years of research. Sangart has refined the pegylation of human hemoglobin to create a molecule, MP4, with the ability to carry oxygen through the circulatory system to the capillaries to perfuse tissues and prevent and treat ischemia. As we continue to study the MP4 molecule and its variations, we aim to help patients suffering from oxygen deprivation of tissues.